|
1
|
Carmeliet P: Angiogenesis in life, disease
and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29(Suppl 16): 15–18. 2002.
View Article : Google Scholar
|
|
3
|
Varinska L, Gal P, Mojzisova G, Mirossay L
and Mojzis J: Soy and breast cancer: Focus on angiogenesis. Int J
Mol Sci. 16:11728–11749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS and Fidler IJ: Angiogenesis and
lung cancer: Potential for therapy. Clin Cancer Res. 6:4604–4606.
2000.
|
|
5
|
Onishi M, Ichikawa T, Kurozumi K and Date
I: Angiogenesis and invasion in glioma. Brain Tumor Pathol.
28:13–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pollitt MJ, Hanby AM, Horgan K, Murphy CE,
Jones PF and Speirs V: Angiogenesis in breast cancer: How should we
measure this? (Review). Oncol Rep. 13:931–936. 2005.PubMed/NCBI
|
|
7
|
Herbst RS, Onn A and Sandler A:
Angiogenesis and lung cancer: Prognostic and therapeutic
implications. J Clin Oncol. 23:3243–3256. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato Y: Molecular diagnosis of tumor
angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol.
8:200–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Hinsbergh VW, Collen A and Koolwijk P:
Angiogenesis and anti-angiogenesis: Perspectives for the treatment
of solid tumors. Ann Oncol. 10(Suppl 4): 60–63. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duarte IG, Bufkin BL, Pennington MF, Gal
AA, Cohen C, Kosinski AS, Mansour KA and Miller JI: Angiogenesis as
a predictor of survival after surgical resection for stage I
non-small-cell lung cancer. J Thorac Cardiovasc Surg. 115:652–658;
discussion 658–659. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Folkman J: Endogenous inhibitors of
angiogenesis. Harvey Lect. 92:65–82. 1997.
|
|
12
|
Gyenge M, Amagase K, Kunimi S, Matsuoka R
and Takeuchi K: Roles of pro-angiogenic and anti-angiogenic factors
as well as matrix metalloproteinases in healing of NSAID-induced
small intestinal ulcers in rats. Life Sci. 93:441–447. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marjon PL, Bobrovnikova-Marjon EV and
Abcouwer SF: Expression of the pro-angiogenic factors vascular
endothelial growth factor and interleukin-8/CXCL8 by human breast
carcinomas is responsive to nutrient deprivation and endoplasmic
reticulum stress. Mol Cancer. 3:42004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hellberg C, Ostman A and Heldin CH: PDGF
and vessel maturation. Recent Results Cancer Res. 180:103–114.
2010. View Article : Google Scholar
|
|
15
|
Alfaro C, Suarez N, Gonzalez A, Solano S,
Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A,
Lopez-Picazo JM, et al: Influence of bevacizumab, sunitinib and
sorafenib as single agents or in combination on the inhibitory
effects of VEGF on human dendritic cell differentiation from
monocytes. Br J Cancer. 100:1111–1119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thompson Coon J, Hoyle M, Green C, Liu Z,
Welch K, Moxham T and Stein K: Bevacizumab, sorafenib tosylate,
sunitinib and temsirolimus for renal cell carcinoma: A systematic
review and economic evaluation. Health Technol Assess. 14:1–184.
iii–iv. 2010. View
Article : Google Scholar
|
|
17
|
Willatt JM, Francis IR, Novelli PM,
Vellody R, Pandya A and Krishnamurthy VN: Interventional therapies
for hepatocellular carcinoma. Cancer Imaging. 12:79–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu AX, Duda DG, Sahani DV and Jain RK:
HCC and angiogenesis: Possible targets and future directions. Nat
Rev Clin Oncol. 8:292–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Burns JM, Summers BC, Wang Y, Melikian A,
Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ,
et al: A novel chemokine receptor for SDF-1 and I-TAC involved in
cell survival, cell adhesion, and tumor development. J Exp Med.
203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Finn RS and Zhu AX: Targeting angiogenesis
in hepatocellular carcinoma: Focus on VEGF and bevacizumab. Expert
Rev Anticancer Ther. 9:503–509. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Balabanian K, Lagane B, Infantino S, Chow
KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M and
Bachelerie F: The chemokine SDF-1/CXCL12 binds to and signals
through the orphan receptor RDC1 in T lymphocytes. J Biol Chem.
280:35760–35766. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boldajipour B, Mahabaleshwar H, Kardash E,
Reichman-Fried M, Blaser H, Minina S, Wilson D, Xu Q and Raz E:
Control of chemokine-guided cell migration by ligand sequestration.
Cell. 132:463–473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Shiozawa Y, Wang J, Wang Y, Jung
Y, Pienta KJ, Mehra R, Loberg R and Taichman RS: The role of
CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate
cancer. J Biol Chem. 283:4283–4294. 2008. View Article : Google Scholar
|
|
24
|
Zheng K, Li HY, Su XL, Wang XY, Tian T, Li
F and Ren GS: Chemokine receptor CXCR7 regulates the invasion,
angiogenesis and tumor growth of human hepatocellular carcinoma
cells. J Exp Clin Cancer Res. 29:312010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iwakiri S, Mino N, Takahashi T, Sonobe M,
Nagai S, Okubo K, Wada H, Date H and Miyahara R: Higher expression
of chemokine receptor CXCR7 is linked to early and metastatic
recurrence in pathological stage I nonsmall cell lung cancer.
Cancer. 115:2580–2593. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Carson-Walter E and Walter KA:
Targeting chemokine receptor CXCR7 inhibits glioma cell
proliferation and mobility. Anticancer Res. 35:53–64.
2015.PubMed/NCBI
|
|
27
|
Lin L, Han MM, Wang F, Xu LL, Yu HX and
Yang PY: CXCR7 stimulates MAPK signaling to regulate hepatocellular
carcinoma progression. Cell Death Dis. 5:e14882014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xue TC, Jia QA, Bu Y, Chen RX, Cui JF,
Tang ZY and Ye SL: CXCR7 correlates with the differentiation of
hepatocellular carcinoma and suppresses HNF4α expression through
the ERK pathway. Oncol Rep. 32:2387–2396. 2014.PubMed/NCBI
|
|
29
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Castello G, Scala S, Palmieri G, Curley SA
and Izzo F: HCV-related hepatocellular carcinoma: From chronic
inflammation to cancer. Clin Immunol. 134:237–250. 2010. View Article : Google Scholar
|
|
31
|
Karin M and Greten FR: NF-kappaB: Linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feldmann M: Development of anti-TNF
therapy for rheumatoid arthritis. Nat Rev Immunol. 2:364–371. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maeda S, Hikiba Y, Sakamoto K, Nakagawa H,
Hirata Y, Hayakawa Y, Yanai A, Ogura K, Karin M and Omata M: Ikappa
B kinasebeta/nuclear factor-kappaB activation controls the
development of liver metastasis by way of interleukin-6 expression.
Hepatology. 50:1851–1860. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Naugler WE, Sakurai T, Kim S, Maeda S, Kim
K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due
to sex differences in MyD88-dependent IL-6 production. Science.
317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park EJ, Lee JH, Yu GY, He G, Ali SR,
Holzer RG, Osterreicher CH, Takahashi H and Karin M: Dietary and
genetic obesity promote liver inflammation and tumorigenesis by
enhancing IL-6 and TNF expression. Cell. 140:197–208. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ren Y, Poon RT, Tsui HT, Chen WH, Li Z,
Lau C, Yu WC and Fan ST: Interleukin-8 serum levels in patients
with hepatocellular carcinoma: Correlations with
clinicopathological features and prognosis. Clin Cancer Res.
9:5996–6001. 2003.PubMed/NCBI
|
|
37
|
Welling TH, Fu S, Wan S, Zou W and Marrero
JA: Elevated serum IL-8 is associated with the presence of
hepatocellular carcinoma and independently predicts survival.
Cancer Invest. 30:689–697. 2012. View Article : Google Scholar : PubMed/NCBI
|
